Roche Holding


BIC22 takeaways

20/09/22 -"During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with ..."

Pages
71
Language
English
Published on
20/09/22
You may also be interested by these reports :
17/07/25
The Q2 sales growth, despite being impacted by adverse FX movements, impressed the markets. Both the segments contributed healthily to the quarterly ...

17/07/25
Q2 results were somewhat ahead of expectations, supported by healthy momentum across focus areas. Management also raised its full-year profitability ...

14/07/25
We have refined our estimates for the forecasting period by removing the €100m financing measure and the associated issuance of approximately 14 ...

14/07/25
BioNTech’s acquisition of CureVac was a strategic move. This decision resolves potential costly issues, including the patent dispute with CureVac, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO